Investors may be interested in the following health care companies, as they have expanded their revenue per share and Ebitda per share by more than 10% over the trailing five-year and 10-year periods through April 28.
UnitedHealth Group
UnitedHealth Group Inc.'s (UNH) revenue per share and Ebitda per share have increased 10.20% and 14.70%, respectively, over the past five years. Over a 10-year period, they grew by 13.10% and 12.80%.
The U.S. private health insurance provider has a market cap of $369.63 billion and an enterprise value of $392.97 billion.
The price-book ratio is 5.33. The share price has been as high as $393.92 and as low as $273.25 in the last year; it is currently 0.74% below its 52-week high and 43.10% above its 52-week low.
The company's largest guru shareholder is Vanguard Health Care Fund (Trades, Portfolio) with 0.90% of outstanding shares, followed by Dodge & Cox with 0.55% and Steve Mandel (Trades, Portfolio) with 0.34%.
Thermo Fisher Scientific
Over the past five years, Thermo Fisher Scientific Inc. (TMO) has seen its revenue increase 13.20% and its Ebitda rise 19.60%. Over a 10-year period, the increases were 10.90% and 16.30%, respectively.
The company, which provides scientific instruments and laboratory equipment, has a market cap of $193.73 billion and an enterprise value of $205.14 billion.
The price-earnings ratio is 30.90. The share price has been as high as $532.57 and as low as $316.36 in the last year; it is currently 7.45% below its 52-week high and 55.81% above its 52-week low.
The company's largest guru shareholder is PRIMECAP Management (Trades, Portfolio) with 1.12% of outstanding shares, followed by Vanguard Health Care Fund (Trades, Portfolio) with 0.74%, BAILLIE GIFFORD & CO with 0.55% and Pioneer Investments (Trades, Portfolio) with 0.46%.
CSL
The revenue per share of CSL Ltd. (CSLLY) has grown by 14.70% and its Ebitda per share has increased by 14.60% over a five-year period. Over the past 10 years, the metrics increased by 15.60% and 15.40%, respectively.
The biotech company has a market cap of $95.30 billion and an enterprise value of $99.02 billion.
The price-earnings ratio is 33.77 and the price-book ratio is 11.56. The share price has been as high as $117.98 and as low as $91.04 in the last year; it is currently 11.26% below its 52-week high and 15% above its 52-week low.
The company's largest guru shareholder is Ken Fisher (Trades, Portfolio) with 0.04% of outstanding shares.
Humana
Over a five-year period, the revenue per share and Ebitda per share of Humana Inc. (HUM) have grown by 10.10% and 16.70%, respectively. Over a 10-year period, the company has reported a growth of 10.50% for its Ebitda and 10.60% for its revenue.
The U.S. private health insurer has a market cap of $56.16 billion and an enterprise value of $58.46 billion.
The price-earnings ratio is 17.21. The share price has been as high as $474.70 and as low as $356 in the last year; it is currently 8.30% below its 52-week high and 22.27% above its 52-week low.
The company's largest guru shareholder is the Vanguard Health Care Fund (Trades, Portfolio) with 1.24% of outstanding shares, followed by Mandel with 1.17% and Jim Simons (Trades, Portfolio)' Renaissance Technologies with 0.74%.
M3
M3 Inc. (MTHRY) registered a five-year performance for its revenue per share of 19.80% and for its Ebitda per share of 16.60%. Over a 10-year period, the growth rates were 28.10% and 19.90%, respectively.
The company, which provides medical-related services, has a market cap of $53.10 billion and an enterprise value of $52.30 billion.
The price-earnings ratio is 185. The share price has been as high as $45.61 and as low as $33.41 in the last three months; it is currently 23.42% below its three-month high and 4.55% above its three-month low.
Disclosure: I do not own any stocks mentioned.
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
